BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Peptide Aptamers: Precision Tools for Early Development of Novel T
 herapeutic Compounds
DTSTART:20131001T141500
DTEND:20131001T151500
DTSTAMP:20260406T173629Z
UID:c587730925e3b17a9958afc619a1032e5ebcadec8103467852ee1b2a
CATEGORIES:Conferences - Seminars
DESCRIPTION:Brian B. Rudkin\, Ph.D.\, CNRS/Ecole Normale Supérieure de Ly
 on (F)\nBio: Dr. Rudkin is a Research Director at the CNRS\, Head of a res
 earch group at the Ecole Normale Supérieure de Lyon\, one of the top Fren
 ch academic research institutions\, Laboratory of Molecular and Cellular B
 iology since 1990 and Co-Director of the Joint Laboratory on Neuropathogen
 esis at the ECNU along with Prof. ChongGang YUAN at East China Normal Univ
 ersity (ECNU) in Shanghai since 2009. Prior to this\, he was Senior Staff 
 fellow at the National Institutes of Health (NICHD) USA\, with G. Guroff (
 Nerve growth factor (NGF) signaling)\, subsequent to Post-Doctoral experie
 nce with G. Thomas (S6 Kinase) then J. Jiricny (G/T Mismatch binding prote
 ins)\, at the Friedrich Miescher Institut of now NOVARTIS\, Basel\, Switze
 rland\, after a PhD from the Department of BioChemistry & BioPhysics\, Uni
 versity of Pennsylvania.\nThe group has dissected pathways involved in NGF
  signaling. Notably\, they were first to describe those responsible for ce
 ll cycle phase-specific anti-mitogenic and differentiation responses. This
  led from the regulation of promoter function to trafficking\, fate and id
 entification of partners of NGF receptors that impact upon the signaling o
 utcome from lipid rafts. The focus of applied research in the laboratory i
 mplements the peptide aptamers to identify novel therapeutic molecules tow
 ards existing validated therapeutic targets and to identify and validate n
 ovel targets for therapeutic intervention with particular focus on signali
 ng pathway(s) involved in cancer and neurodegenerative diseases.\nDr. Rudk
 in is a member of the Executive committee for the coordination of the "Qua
 lity of Life and Aging" Research Cluster of the Rhone-Alps Region that enc
 ompasses research laboratories\, small innovative companies\, large multin
 ationals\, university hospitals and patient organizations to better serve 
 the needs of society regarding these concerns. He is also on the investmen
 t committee of CREALYS\, the regional incubator for accompanying innovativ
 e projects from research laboratories since its inception in 1999. Dr. Rud
 kin has accompanied a number of innovative companies in their creation and
  development over the years\, as external advisor or partner.\nWhile syste
 ms biology approaches analyzing the genome\, proteome\, interactome etc. a
 re increasing our understanding of complex regulatory networks\, identific
 ation of key proteins in signaling pathways that regulate cellular respons
 es remains crucial for furthering our understanding of normal cellular pro
 cesses and pathological perturbations thereof. Peptide aptamers\, conceive
 d to conceptually resemble antibodies\, are small combinatorial proteins w
 ith a constant scaffold presenting a variable region. Their use for the id
 entification and validation of novel targets and discovery of novel therap
 eutics in vitro\, in cellular models\, and in vivo in animal models for hu
 man disease\, will be discussed.
LOCATION:SV1717a http://map.epfl.ch/?room=sv1717a
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR